doi: 10.1016/j.physbeh.2019.112771, 83 KreymannB.WilliamsG.GhateiM
Last month, CVS Caremark announced that it had struck a deal to make Novo's Wegovy its primary weight loss drug starting in the second half of the year, which would mean coverage for Lilly's Zepbound would no longer be preferred
Currently, several obesity companies, such as YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis,, and others, across the globe are developing obesity therapies
Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities
"Some might call NAD+ a miracle cure for aging, but is it worth the hype
Cagrilintide is not intended to be used for tissue regeneration, clinical treatment, or any therapeutic purpose